William D. Collins

Mr. Collins’s recent client representations include the following:

• Magenta Therapeutics in connection with
  • its $48.5 million Series A financing
  • its $50 million Series B financing 
  • its strategic collaborations with Novartis and BeTheMatch
  • its $100.0 million initial public offering
• Intellia Therapeutics in connection with:
  • its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology
  • its collaboration and license agreements with Novartis and Regeneron
  • its $124.2 million initial public offering
  • its $150.0 follow-on public offering
• Nimbus Therapeutics in connection with:
  • its multi-target strategic alliance with Celgene Corporation in immunology
  • the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences
  • its $43 million Series B financing
• Padlock Therapeutics in connection with:
  • its $23 million Series A financing to develop medicines targeting PADs and immune complexes in autoimmune diseases
  • its $600 million sale to Bristol-Meyers Squibb
• Relay Therapeutics in connection with:
  • its $57 million Series A financing
  • its $63 million Series B financing
• TCR² Therapeutics in connection with:
  • its $44.5 million Series A financing
  • its $125.0 million Series B Financing
• Tango Therapeutics in its $55 million Series A financing
• Kymera Therapeutics in its $30 million Series A financing
• Obsidian Therapeutics in its $49.5 million Series A financing
• Casma Therapeutics in its $58.5 million Series A financing
• Celsius Therapeutics in its $65 million Series A financing
• Rheos Medicines in its $60 million Series A financing

Public Company Representation and Capital Markets Transactions

• AMAG Pharmaceuticals in numerous follow-on equity offerings, convertible note offerings and its high-yield bond offering, raising more than $1.4 billion in capital, and its transformative acquisitions of CBR Systems and other strategic transactions 
• Amarin Corporation in its $121.2 million, $87.5 million and $56.1 million follow-on offerings, its $53 million PIPE offering, its $150 million 144A note offering and a $118.7 privately negotiated note exchange
• bluebird bio in its $116.1 million initial public offering

Mergers and Acquisitions

• Ocata Therapeutics in its sale to Astellas 
• Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
• Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
• ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions

Mr. Collins also represents leading life science venture capital and investment firms, including Atlas Venture, Third Rock Ventures and Deerfield, in connection with their portfolio investments and related matters.